SM-2235

N/A

Report date: 2024/11/20 14:15:32

Base Information

Drug NameSM-2235
Drug Alias NameSM-2235SM2235
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsLow affinity immunoglobulin gamma Fc region receptor III-A agonists
TargetsEpidermal growth factor receptor erbB1Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhuhai StarMab BioMed Technology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai StarMab BioMed Technology Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A